NATAP -
www.natap.org**************************************************************
Retrovirus Conference 2003 Coverage
New Drugs for HIV
**************************************************************
Entry Inhibitors, The How and Why of New Agents at Retrovirus: an Update, by
Christopher Pilcher, MD
http://www.natap.org/2003/Retro/day34.htmNew antiretroviral agents: bright lights on the horizon, by David Margolis, MD
http://www.natap.org/2003/Retro/day9.htm"908": New Formulation of Amprenavir
http://www.natap.org/2003/Retro/day13.htmTipranavir Report: phase II dose study
http://www.natap.org/2003/Retro/day15.htmNew HIV Antiretroviral Drugs: atazanavir resistance, T-1249 for T-20
resistance, plus more
http://www.natap.org/2003/Retro/day2.htmNew HIV Drugs at Retrovirus 2003, by Mike Youle, MD
http://www.natap.org/2003/Retro/day36.htmTNX-355, anti-CD4 monoclonal antibody: Safety and preliminary Anti-HIV
Activity
http://www.natap.org/2003/Retro/day42.htmUK-427,857: new entry inhibitor, CCR5 antagonist
http://www.natap.org/2003/Retro/day21.htmFull Retrovirus Coverage, 45 reports so far (lipodystrophy,
STIs/interruptions, Hep C & B, acute HIV, reservoirs, hot clinical studies).
More coming.
http://www.natap.org/2003/Retro/ndxRetro.htm